CorMedix Q2 Earnings Call Highlights
CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.
How this was made
The 30-second read
Why it matters
Traders can update valuation assumptions around 2026 profitability and the probability/timing of regulatory action for REZZAYO, plus ongoing DefenCath trial de-risking via protocol amendment and site activation.
Market read
Guidance updates and specific regulatory/clinical timelines provide actionable catalyst mapping for the next several quarters.
What to watch
The article notes no Medicare Advantage contribution in 2026 guidance and that REZZAYO filing depends on Mundipharma submission and FDA acceptance, leaving execution risk into 2027.
Background
The piece summarizes CorMedix’s Q2 earnings call, including financial results, full-year 2026 guidance, and updates on REZZAYO and DefenCath clinical programs.
Ticker impact
CorMedix reaffirmed 2026 revenue guidance and raised adjusted EBITDA outlook, while outlining REZZAYO NDA filing timing and DefenCath Phase 3 updates.
Bias modestly positive, with upside skew if investors view REZZAYO filing and DefenCath trial progress as de-risking catalysts into 2027.
The article provides concrete financial guidance changes plus specific regulatory and clinical timelines that affect probability-weighted cash flows, but it is still an earnings-call highlight rather than a new filing approval or contract award.
Market effects
Reinforces investor focus on dialysis infection prevention and antifungal prophylaxis development timelines in small-cap biopharma.
Limited direct regional impact; FDA-related timing is US-centric.
Moderate, as REZZAYO and dialysis infection prevention have broader international clinical relevance, but the catalysts cited are US regulatory and trial milestones.
Counterpoint
Raised EBITDA outlook may be partially offset by higher operating expense run-rate and reliance on future real-world evidence and contracting timelines.
Key entities
- companyCorMedix
NASDAQ-listed clinical-stage biopharma focused on dialysis infection prevention and antifungal prophylaxis development.
- partnerMundipharma
Partner expected to submit a supplemental new drug application for REZZAYO in Q3.
- regulatorFDA
Agency action anticipated in the first half of 2027 if the supplemental NDA is timely submitted and accepted.
